Department of Gastroenterology, Huai'an Huai'an Hospital, Huai'an, Jiangsu 223200, China.
Cell Mol Biol (Noisy-le-grand). 2024 Jul 28;70(7):128-133. doi: 10.14715/cmb/2024.70.7.18.
To assess the diagnostic efficacy of SEPT9 along with PAX5 gene methylation detection in gastrointestinal cancer and precancerous lesions, the peripheral blood of 62 patients with gastric cancer (GC) and 60 patients with no evidence of disease (as the control group) were retrospectively collected. The methylation rates of PAX5 and SEPT9 gene promoters in blood samples of GC group were detected by PCR. At the same time, the differences in methylation rates of genes in the two groups were compared, and the predictive value of plasma methylation PAX5 and SEPT9 in GC was evaluated by receiver operating characteristic (ROC) curve. We found that there were 41 cases of methylated PAX5 gene promoter region and 39 cases of methylated SEPT9 gene promoter region in GC group. The control group contained 14 cases of PAX5 gene promoter methylation and 12 cases of RNF¹80 gene promoter methylation. The occurrence of PAX5 promoter methylation was correlated with age of GC patients. There were statistically significant differences in mSEPT9 gene in patients with different TNM stages. Kaplan-Meier survival curve analysis revealed that the three-year overall survival rate of GC patients with PAX5 methylation was lower than that of GC patients without PAX5 methylation. No significant difference was discovered in 3-year overall survival rate between GC patients with SEPT9 methylation and those without SEPT9 methylation. Combined detection could not improve the diagnostic value of GC, but could promote diagnosis sensitivity. In summary, the risk of PAX5 and SEPT9 gene methylation in GC patients presents higher when compared with healthy people. PAX5 gene methylation is closely related to age, while SEPT9 is closely related to tumor TNM stage, and PAX5 gene methylation can decrease the survival rate of GC patients. Detection of PAX5 gene methylation level can assist in evaluating the prognosis of GC patients.
为了评估 SEPT9 与 PAX5 基因甲基化检测在胃肠道癌及癌前病变中的诊断效能，回顾性收集了 62 例胃癌（GC）患者和 60 例无疾病证据（作为对照组）的外周血。采用 PCR 法检测 GC 组患者血液样本中 PAX5 和 SEPT9 基因启动子的甲基化率。同时比较两组基因甲基化率的差异，采用受试者工作特征（ROC）曲线评价血浆甲基化 PAX5 和 SEPT9 对 GC 的预测价值。结果发现，GC 组中 PAX5 基因启动子区甲基化 41 例，SEPT9 基因启动子区甲基化 39 例；对照组中 PAX5 基因启动子区甲基化 14 例，RNF¹80 基因启动子区甲基化 12 例。GC 患者 PAX5 启动子甲基化的发生与年龄相关，不同 TNM 分期患者 mSEPT9 基因存在统计学差异。Kaplan-Meier 生存曲线分析显示，PAX5 甲基化的 GC 患者 3 年总生存率低于 PAX5 未甲基化的 GC 患者。SEPT9 甲基化的 GC 患者与未甲基化的 GC 患者 3 年总生存率无明显差异。联合检测不能提高 GC 的诊断价值，但可以提高诊断的敏感性。综上所述，GC 患者 PAX5 和 SEPT9 基因甲基化的风险高于健康人群。PAX5 基因甲基化与年龄密切相关，而 SEPT9 与肿瘤 TNM 分期密切相关，PAX5 基因甲基化可降低 GC 患者的生存率。检测 PAX5 基因甲基化水平有助于评估 GC 患者的预后。
